JP2024505072A - イヌ科動物抗体の定常領域における変異 - Google Patents

イヌ科動物抗体の定常領域における変異 Download PDF

Info

Publication number
JP2024505072A
JP2024505072A JP2023545996A JP2023545996A JP2024505072A JP 2024505072 A JP2024505072 A JP 2024505072A JP 2023545996 A JP2023545996 A JP 2023545996A JP 2023545996 A JP2023545996 A JP 2023545996A JP 2024505072 A JP2024505072 A JP 2024505072A
Authority
JP
Japan
Prior art keywords
igg
constant domain
canine
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505072A5 (cg-RX-API-DMAC10.html
Inventor
カンポス,ヘンリー・ルイス
ライトル,サンドラ・アン・マリー
バージェロン,リサ・マリー
Original Assignee
ゾエティス・サービシーズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾエティス・サービシーズ・エルエルシー filed Critical ゾエティス・サービシーズ・エルエルシー
Publication of JP2024505072A publication Critical patent/JP2024505072A/ja
Publication of JP2024505072A5 publication Critical patent/JP2024505072A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023545996A 2021-01-28 2022-01-27 イヌ科動物抗体の定常領域における変異 Pending JP2024505072A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28
US63/142,774 2021-01-28
PCT/US2022/014146 WO2022165067A2 (en) 2021-01-28 2022-01-27 Mutations in canine antibody constant regions

Publications (2)

Publication Number Publication Date
JP2024505072A true JP2024505072A (ja) 2024-02-02
JP2024505072A5 JP2024505072A5 (cg-RX-API-DMAC10.html) 2025-01-24

Family

ID=80786846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545996A Pending JP2024505072A (ja) 2021-01-28 2022-01-27 イヌ科動物抗体の定常領域における変異

Country Status (15)

Country Link
US (1) US20240059777A1 (cg-RX-API-DMAC10.html)
EP (2) EP4512416A3 (cg-RX-API-DMAC10.html)
JP (1) JP2024505072A (cg-RX-API-DMAC10.html)
KR (1) KR20230136604A (cg-RX-API-DMAC10.html)
CN (1) CN116802205A (cg-RX-API-DMAC10.html)
AU (1) AU2022214843A1 (cg-RX-API-DMAC10.html)
CA (1) CA3207285A1 (cg-RX-API-DMAC10.html)
CL (4) CL2023002202A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009994A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23057156A (cg-RX-API-DMAC10.html)
IL (1) IL304522A (cg-RX-API-DMAC10.html)
MX (1) MX2023008785A (cg-RX-API-DMAC10.html)
PE (1) PE20231919A1 (cg-RX-API-DMAC10.html)
TW (1) TW202246318A (cg-RX-API-DMAC10.html)
WO (1) WO2022165067A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
MX2023008785A (es) 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.
AU2023334358A1 (en) * 2022-09-02 2025-03-13 Zoetis Services Llc Porcine antibody mutants
WO2026125320A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
CN121574951B (zh) * 2026-01-27 2026-04-28 金发科技股份有限公司 一种苹果酸脱氢酶、含有其的工程化库德里亚兹毕赤酵母及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020142625A2 (en) * 2019-01-03 2020-07-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MX2023008785A (es) 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018073185A1 (en) * 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
WO2020082048A1 (en) * 2018-10-18 2020-04-23 Kindred Biosciences, Inc. Fc variants with altered binding to neonatal fc receptor (fcrn) for veterinary use
WO2020142625A2 (en) * 2019-01-03 2020-07-09 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use

Also Published As

Publication number Publication date
CL2025001754A1 (es) 2026-04-17
MX2023008785A (es) 2023-12-14
CL2024001562A1 (es) 2024-08-23
AU2022214843A9 (en) 2024-05-16
EP4512416A2 (en) 2025-02-26
CO2023009994A2 (es) 2023-08-09
CN116802205A (zh) 2023-09-22
CL2023002202A1 (es) 2024-01-12
AU2022214843A1 (en) 2023-07-20
CL2026000660A1 (es) 2026-06-26
US20240059777A1 (en) 2024-02-22
EP4284825A2 (en) 2023-12-06
PE20231919A1 (es) 2023-11-28
ECSP23057156A (es) 2023-08-31
CA3207285A1 (en) 2022-08-04
EP4512416A3 (en) 2025-06-18
KR20230136604A (ko) 2023-09-26
IL304522A (en) 2023-09-01
WO2022165067A3 (en) 2022-09-22
WO2022165067A2 (en) 2022-08-04
TW202246318A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
US20240059777A1 (en) Mutations in canine antibody constant regions
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
JP2023522029A (ja) イヌ科動物抗体バリアント
JP2023522030A (ja) ネコ科動物抗体バリアント
JP2023543262A (ja) イヌ科動物抗体バリアント
JP2023551194A (ja) ウシ科動物抗体バリアント
TWI880316B (zh) 貓抗體變異體
RU2840969C1 (ru) Варианты кошачьих антител
JP2025525987A (ja) ウシ亜科動物抗体変異体
JP2025524441A (ja) イヌ科動物抗体変異体
JP2025529206A (ja) 豚抗体変異体
JP2025533894A (ja) ブタ抗体変異体
HK40121344A (en) Mutations in canine antibody constant regions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260702